

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 487/10, A61K 31/47</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/00393</b>
			(43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: <b>PCT/KR98/00185</b>			(KR). JIN, Yoon-Ho [KR/KR]; 96-39, Sinlim 2-dong, Kwanak-ku, Seoul 151-012 (KR).
(22) International Filing Date: 26 June 1998 (26.06.98)			(74) Agent: PARK, Sa-Ryong; #301 Chongho Building, 823-5, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).
(30) Priority Data: 1997/27806 26 June 1997 (26.06.97) KR 1998/1609 20 January 1998 (20.01.98) KR			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): DONG WHA PHARMACEUTICAL INDUSTRIAL CO., LTD. [KR/KR]; 5, Soonwha-dong, Choong-ku, Seoul 100-130 (KR).			<b>Published</b> With international search report.
(72) Inventors; and (75) Inventors/Applicants (for US only): YOON, Sung-Joon [KR/KR]; 1420-11, Sinlim 5-dong, Kwanak-ku, Seoul 151-015 (KR). CHUNG, Yong-Ho [KR/KR]; #301-204, Saemmaeul Apt., Hoge-dong, Dongan-ku, Anyang, Kyunggi-do 431-080 (KR). LEE, Chi-Woo [KR/KR]; #207-201, Jugong Apt., Sanbon-dong, Kunpo, Kyunggi-do 435-040 (KR). OH, Yoon-Seok [KR/KR]; #207, Hyunam Apt., 164-11, Anyang 7-dong, Manan-ku, Anyang, Kyunggi-do 430-017 (KR). KIM, Nam-Doo [KR/KR]; #102-306, Hyundai 1-cha Apt., 628, Okryun-dong, Yonsu-ku, Incheon 406-050 (KR). LIM, Jae-Kyung [KR/KR]; #3-202, Yuchang Villa, 198-66, Anyang 7-dong, Manan-ku, Anyang, Kyunggi-do 430-017			
(54) Title: QUINOLONE CARBOXYLIC ACID DERIVATIVES			
<div style="text-align: center;"><p>(1)</p></div>			
(57) Abstract			
<p>The present invention relates to quinolonecarboxylic acid derivatives having more excellent and broad antibacterial activities than the existing quinolone-series antibiotics. More specifically, it pertains to novel quinolonecarboxylic acid derivatives represented by formula (1), which have a derivative of 7-[8-(alkoxyimino)-2,6-diazaspiro[3,4]oct-6-yl] as a substituent, and pharmaceutically acceptable salts and isomers thereof; wherein A is C-H, C-F, C-Cl, C-O-CH<sub>3</sub> or N; Y is H or amino; R<sub>1</sub> is cyclopropyl or 2,4-difluorophenyl; R<sub>2</sub> is C<sub>1-4</sub> alkyl; and R<sub>3</sub> is H or C<sub>1-4</sub> alkyl.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## QUINOLONE CARBOXYLIC ACID DERIVATIVES

FIELD OF THE INVENTION

5       The present invention relates to quinolonecarboxylic acid derivatives having more excellent and broad antibacterial activities than the existing quinolone-series antibiotics. More specifically, it pertains to novel quinolonecarboxylic acid derivatives represented by following formula 1, which have a derivative of 7-[8-(alkoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]

10 as a substituent, and pharmaceutically acceptable salts and isomers thereof:



Wherein, A is C-H, C-F, C-Cl, C-O-CH<sub>3</sub> or N; Y is H or amino;  
20 R<sub>1</sub> is cyclopropyl or 2,4-difluorophenyl; R<sub>2</sub> is C<sub>1-4</sub> alkyl; and R<sub>3</sub> is H or C<sub>1-4</sub> alkyl.

BACKGROUND OF THE INVENTION

25       Quinolonecarboxylic acid derivatives are synthetic antibiotics which are well known to be useful for the treatment of infective diseases in human and animals due to their potent and broad antibacterial activities. Quinolone-series antibiotics such as norfloxacin, ofloxacin and ciprofloxacin are currently used very usefully for the treatment of human diseases and

30 their efficacies are acknowledged. However, these medicines have a problem that: even though they show excellent antibacterial activities against gram-negative bacteria, they still show ordinary or relatively low


- 2 -

antibacterial activities against gram-positive bacteria. Accordingly, there have been various studies for solving such problems of existing quinolone-series antibiotics and, finally, sparfloxacin having improved antibacterial activities against gram-positive bacteria has been developed.

5 However, this compound still shows weak antibacterial activities against *Streptococci*, methicillin resistant *Staphylococcus aureus*(MRSA) and other currently increasing quinolone-resistant strains. These strains are well known as pathogens of the respiratory infections. Therefore, there are increasing needs for the development of improved quinolone  
10 antibiotics which exhibit excellent antibacterial activities against such quinolone-resistant strains.

On the other hand, Korean patent laid-open publication Nos. 96-873, 96-22501 and 96-22502, and EP688772A1 disclose quinolone-series antibacterial agents of following formulae 16, 17 and 18:

15




20

16

Wherein, Q is C-H, C-F, C-Cl, C-OH, C-O-CH<sub>3</sub> or N; R is H, methyl or amino; R<sub>1</sub> is cyclopropyl, ethyl, or phenyl substituted with more than one fluorine atom; R<sub>2</sub> is H, C<sub>1-4</sub> straight or branched alkyl, phenyl or  
25 allyl.

30



17

Wherein, R is H, methyl or amino; Q is C-H, C-F, C-Cl, C-CH<sub>3</sub>.


- 3 -

C-O-CH<sub>3</sub> or N; R<sub>1</sub> is cyclopropyl, ethyl, or phenyl substituted with one or more fluorine atoms; R<sub>2</sub> is C<sub>3</sub>-C<sub>4</sub> branched alkyl such as t-butyl and cyclopropylmethyl, C<sub>3</sub>-C<sub>6</sub> alkyl having a triple bond such as propargyl and homopropargyl, 2-haloethyl, methoxymethyl, methoxycarbonylmethyl, or a

5 group having the following formula:



10       Wherein, n is 0 or 1; m is 0, 1 or 2; x is methylene, O or N; R<sub>3</sub> and R<sub>4</sub> are independently H or C<sub>1</sub>-C<sub>3</sub> alkyl group, or they may form a ring with a nitrogen group to which they are attached.



18


20   Wherein,

R is H, methyl or amino group;

Q is C-H, C-F, C-Cl, C-CH<sub>3</sub>, C-O-CH<sub>3</sub> or N;

R<sub>1</sub> is cyclopropyl, ethyl, or phenyl group substituted with one or more fluorine atom;

25   R<sub>2</sub> is a group of following formula a :




a

30

Wherein, X is 2-, 3- or 4-fluoro, cyano, nitro, methoxy, methyl or C<sub>1</sub>-C<sub>4</sub> alkyl group, or 2,4-difluoro group;

- 4 -

a group of following formula b:




5

b

; or

an arylmethyl group containing a hetero group of following formula

c:



10

c

$R_3$  and  $R_4$  are independently H or  $C_1$ - $C_3$  alkyl group, or they may form a ring with a nitrogen group to which they are attached.

The above compounds are different from the compound of the present invention of the formula 1 in their structures. Specifically, in the compounds disclosed in Korean Patent laid-open publication Nos. 96-873, 96-22501 and 96-22502, and EP688772 A1, an alkoxyimino group is substituted on the pyrrolidine ring, which is a substituent at the 7-position, and the substituents adjacent to the alkoxyimino group such as amino, alkylamino, aminomethyl, alkylaminomethyl are attached to the pyrrolidine ring as a straight chain form. In contrast, in the compounds of the present invention, the pyrrolidine ring substituted at the 7-position having an oxime and its derivatives, forms a diazaspino compound with an azetidine structure. Accordingly, the compounds of the present invention are different from those of the above patent laid-open publications in their structures. In terms of antibacterial activities, the compounds of the present invention show strong antibacterial activities against the recently-increasing quinolone-resistant strains, while the compounds of the above patent laid-open publications exhibit very weak antibacterial activities against the quinolone-resistant strains.

- 5 -

Further, although EP265230 A1 discloses the substitution of diazaspiro compound at 7-position of the quinolone derivative, it specifically discloses only 2,7-diazaspiro[4.4]nonane and 2-methyl-2,7-diazaspiro[4.4]nonane compounds of the following formulae

5



10 and does not specifically disclose 2,6-diazaspiro[3.4]octane compound as disclosed in the present invention. Moreover, there is no mention about the alkoxyimino group introduced in the 2,6-diazaspiro[3.4]octane substituent on the 7-position as disclosed in the present invention. Accordingly, the compounds of the present invention are different from  
15 those of the above-mentioned patent laid-open publications in terms of structure. As to antibacterial activities, the compounds of the present invention exhibit excellent antibacterial activities against the existing quinolone-resistant strains as well as against both of gram-negative and gram-positive bacteria, while the compounds of the above-mentioned  
20 patent laid-open publications have ordinary antibacterial activities against gram-negative and gram-positive bacteria,

The present inventors have endeavored constantly to develop novel quinolonecarboxylic acids which exhibit excellent antibacterial activities against both of gram-negative and gram-positive bacteria, as well as  
25 improved antibacterial activities against such problematic strains as *Streptococci*, methicillin resistant *Staphylococcus aureus*(MRSA) and other currently increasing quinolone-resistant strains.

Finally, the present inventors have accomplished the present invention by discovering that quinolonecarboxylic acids substituted with  
30 7-[8-(alkoxyimino)-2,6-diazaspiro[3.4]oct-6-yl] at the 7-position show excellent antibacterial activities against the above-mentioned strains.


## SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide novel quinolonecarboxylic acid derivatives of the above formula 1, and  
5 pharmaceutically acceptable salts and isomers thereof, which exhibit excellent antibacterial activities against both of gram-negative and gram-positive bacteria and, especially, show superior antibacterial activities against the methicillin-resistant strains, as well as against the existing quinolone-resistant strains.

10 Another object of the present invention is to provide processes for preparing the novel quinolonecarboxylic acid derivatives of the formula 1.

## DETAILED DESCRIPTION OF THE INVENTION

15 The present invention is characterized by quinolonecarboxylic acid derivatives represented by following formula 1, and pharmaceutically acceptable salts and isomers thereof:



25 Wherein, A is C-H, C-F, C-Cl, C-O-CH<sub>3</sub> or N; Y is H or amino; R<sub>1</sub> is cyclopropyl or 2,4-difluorophenyl; R<sub>2</sub> is C<sub>1-4</sub> alkyl; and R<sub>3</sub> is H or C<sub>1-4</sub> alkyl.

The present invention is described in more detail as follows.

30 According to the present invention, the typical examples of quinolone carboxylic acid derivatives of the above formula 1 may be listed as follows:



1-cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

1-cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

5 1-cyclopropyl-6,8-difluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

1-cyclopropyl-6-fluoro-8-chloro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

1-cyclopropyl-5-amino-6,8-difluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

1-(2,4-difluorophenyl)-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

1-(2,4-difluorophenyl)-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

15 1-cyclopropyl-6-fluoro-7-[8-(ethoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

1-cyclopropyl-5-amino-6,8-difluoro-7-[8-(ethoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

1-cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2-methyl-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

1-cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2-methyl-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

1-cyclopropyl-6,8-difluoro-7-[8-(methoxyimino)-2-methyl-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid,

25 1-cyclopropyl-6-fluoro-8-chloro-7-[8-(methoxyimino)-2-methyl-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid, and

1-cyclopropyl-5-amino-6,8-difluoro-7-[8-(methoxyimino)-2-methyl-2,6-diazaspiro[3.4]oct-6-yl]-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid.

The quinolonecarboxylic acid derivatives of the present invention represented by formula 1 have a double bond in the pyrrolidine ring at the 7-position and, accordingly, geometric isomers of cis- or trans-form may be present. The present invention includes all of such geometric isomers.

- 8 -


A pharmaceutically acceptable salts may be prepared from the quinolonecarboxylic acid derivatives of the present invention represented by formula 1, in accordance with some ordinary methods in the art to which the present invention pertains. As one kind of such salts, an acid addition  
 5 salt may be prepared, and exemplary acids to be used therefor include an inorganic acid such as hydrochloric acid, phosphoric acid and sulfuric acid; and an organic acid such as methane sulfonic acid, p-toluene sulfonic acid, acetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid and glucuronic acid. In addition,  
 10 a cation such as sodium or potassium ion may also be used for the preparation of pharmaceutically acceptable salts.

Further, the present invention includes the process of preparing the quinolonecarboxylic acid derivatives represented by formula 1.

The quinolonecarboxylic acid derivatives of the present invention of the  
 15 formula 1 may be prepared by any one of two methods represented by following Reaction schemes 1 and 2.

In the following reaction scheme 1, the compound of following formula 2 is subjected to coupling reaction with the compound of following formula 3 to obtain the desired compound of the present invention, i.e., a  
 20 quinolonecarboxylic acid derivative represented by following formula 1.

[Reaction scheme 1]



30 Wherein, A, Y, R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are respectively as defined above, and X is a halogen atom, preferably, fluorine or chlorine. The compound of formula 2 may be prepared in accordance with the method described in


U. S. Patent No. 4,382,892. The compound of formula 3 may be used in the form of a free base or an acid salt, and the acid salt may be formed by using an acid such as hydrochloric acid, acetic acid and trifluoroacetic acid.

5 To explain the above reaction scheme in more detail, the coupling reaction of the compound of formula 2 with the compound of formula 3 are carried out under the presence of a solvent with the addition of a suitable base(acid acceptor) to obtain a quinolonecarboxylic acid derivative represented by formula 1. The reaction may be completed preferably at 0  
10 to 200°C for 1 to 24 hours with stirring.

As the solvent used in the above reaction, acetonitrile, dimethyl formamid(DMF), dimethylsulfoxide(DMSO) and pyridine are preferred. As the base(acid acceptor), it is preferred to use inorganic bases such as sodium hydrogencarbonate, calcium carbonate, and sodium carbonate, or  
15 organic bases such as triethylamine, diisopropylethylamine, pyridine, lutidine, N,N-dimethylaniline, N,N-dimethylaminopyridine, 1,8-diazabicyclo[5,4,0]undec-7-ene(DBU), 1,5-diazabicyclo[4,3,0]nonene-5(DBN), and 1,4-diazabicyclo[2,2,2]octane(DABCO). Further, the reaction efficiency may  
20 be increased by using an excessive amount(2 to 10 mole equivalents) of the compound of formula 3 as an acid acceptor. The reaction rate may increase by using an ion-exchange resin. Exemplary ion-exchange resin may include Amberlite® IRA-420, Amberlite® IRA-900 and Amberlite® IRA-64.

25 In the second preparation process(Reaction scheme 2), the compound of following formula 2 is subjected to coupling reaction with the compound of following formula 3a to prepare the desired compound of the present invention, i.e., a compound represented by following formula 1 wherein R<sub>3</sub> is H, via an intermediate of following formula 4. Further, the compounds  
30 of formula 1 wherein R<sub>3</sub> is C<sub>1-4</sub> alkyl may be prepared by reductive alkylation of the compounds of formula 1 wherein R<sub>3</sub> is H with lower aldehydes.

## [Reaction scheme 2]



- 11 -


group(P) of the compound of formula 4 thus obtained from the condensation reaction is removed by an alkali hydrolysis or a general deprotection reaction to obtain the compound of formula 1.

For example, the compound of formula 4 is reacted in a solvent under the presence of an acid or base at a temperature ranging from room temperature to 120°C to remove the amine protecting group(P). As an acid for use in the deprotection reaction, an inorganic acid such as hydrochloric acid, bromic acid and sulfuric acid, or an organic acid such as acetic acid, trifluoroacetic acid, formic acid, *p*-toluenesulphonic acid may be used. Further, in case that the amine protecting group(P) is a benzyl, *p*-methoxybenzyl, benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl or trichloroethoxycarbonyl group, the amine protecting group(P) may be removed by the reduction under the hydrogen atmosphere at a temperature ranging from 5 to 100°C using palladium, Raney nickel or platinum.


On the other hand, the compounds of formula 1 wherein R<sub>3</sub> is C<sub>1-4</sub> alkyl may be prepared by reductive alkylation of the compounds of formula 1 wherein R<sub>3</sub> is H with C<sub>1-4</sub> aldehyde under a weak acidic condition by using sodiumcyanoborohydride as a reducing agent at 0 to 50°C.

The compounds of formulae 3 and 3a, which are also the starting materials of the present invention, may be prepared by the following Reaction scheme 3.

[Reaction scheme 3]



- 12 -



Wherein, R<sub>2</sub> and R<sub>3</sub> are as defined above; L is methanesulfonyloxy, *p*-toluenesulfonyloxy, or halogen, preferably fluorine or chlorine; and P' is an amine protecting group such as formyl, acetyl, trifluoroacetyl, benzoyl, alkoxycarbonyl(e.g., ethoxycarbonyl, *t*-butoxycarbonyl, benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, trichloroethoxycarbonyl), benzyl, *p*-methoxybenzyl and trityl.

To explain the process of Reaction scheme 3 in detail, a ketoester compound(formula 5) is reacted with an aqueous formalin solution at 0 to room temperature under the presence of a base to obtain a hydroxyketone compound(formula 6). Suitable bases for this reaction include sodium carbonate, calcium carbonate, sodium hydrogen carbonate, sodium

- 13 -

hydroxide and calcium hydroxide, and suitable solvents include alcohols such as methanol, ethanol and isopropyl alcohol. The compound of formula 6 is reacted with an alkoxyamine to obtain an alkoxyimino pyrrolidine derivative compound of formula 7 in high yields. In this  
5 reaction, pyridine may be used as a solvent, as well as a base. Further, in case that water, tetrahydrofuran or an alcohol(methanol, ethanol, etc.) is used as a solvent, an inorganic base such as sodium hydrogen carbonate and sodium acetate may also be used together with such solvent. In order to convert an hydroxy group(-OH) in the compound of formula 7 to  
10 a suitable leaving group L[methanesulfonyloxy(-OMs), *p*-toluenesulfonyloxy(-OTs), halogen], the hydroxy group is reacted with methanesulfonyl chloride or *p*-toluenesulfonyl chloride under the presence of an organic base such as triethylamine and pyridine at a temperature ranging from 0 to 50°C to obtain the compound of formula 8 wherein the  
15 hydroxy group is substituted with leaving group L. On the other hand, the compound of formula 8 may also be obtained by converting the hydroxy group(-OH) in the compound of formula 7 to halogen according to a conventional method. In the representative example of such halogenation reaction, pyridine is added to triphenylphosphine and  
20 carbontetrabromide(J. Chem. Soc, Perkin Trans. 1, 3549, 1997) and then reacted with the compound of formula 7 to obtain the bromide compound of formula 8. The ester group of the compound of formula 8 thus obtained is reduced by using a suitable reducing agent at a temperature ranging from 0 to reflux temperature of used solvent to obtain the alcohol  
25 compound of formula 9 in a good yield. Representative reducing agent for this reaction is sodium borohydride and the reactivity of sodium borohydride increases by using it together with a lithium salt(lithium chloride or lithium bromide). When sodium azide is reacted with leaving group L in the compound of formula 9, an azidomethyl pyrrolidine  
30 compound(formula 10) is obtained. As a solvent for this reaction, dimethyl formamide(DMF) or dimethyl sulfoxide(DMSO) is preferred. In order to convert a hydroxy group in the azidomethyl pyrrolidine compound(formula

- 14 -

10) to suitable leaving group L[methanesulfonyloxy(-OMs), *p*-toluenesulfonyloxy(-OTs) or halogen], the same reaction as in the conversion of the compound of formula 7 to the compound of formula 8 is conducted under the same condition to obtain the compound of formula 11 wherein the hydroxy group is converted to leaving group L, in a good yield. The azido group in the compound of formula 11 is reduced by using a metal catalyst such as platinum, palladium on carbon(Pd/C) and Raney nickel, or reduced by using triphenylphosphine or triphenylphosphite in an inert solvent such as tetrahydrofuran to obtain aminomethyl pyrrolidine compound(formula 12) in a good yield. When the compound of formula 12 is heated at 50 to 130°C under the presence of a suitable base, a cyclization reaction is occurred to obtain 8-alkoxyimino-2,6-diazaspiro[3,4]octane derivative compound of formula 13. As a solvent for use in this reaction, acetonitrile, dimethylformamide, pyridine and toluene are preferred, and preferred base include organic bases such as triethylamine, diisopropylamine, pyridine, lutidine, *N,N*-dimethylaniline, *N,N*-dimethylaminopyridine, 1,8-diazabicyclo[5,4,0]undec-7-ene(DBU), 1,5-diazabicyclo[4,3,0]nonene-5(DBN) and 1,4-diazabicyclo[2,2,2]octane(DABCO). The amine protecting group P' in the compound of formula 13 is removed, according to the kind of amine protecting group, under the same condition as in the deprotection reaction of amine protecting group P, which reaction is used for the preparation of the compound of formula 1 from the compound of formula 4 as illustrated in Reaction scheme 2, to obtain the compound of formula 3 wherein R<sub>3</sub> is H. On the other hand, the compound of formula 3 wherein R<sub>3</sub> is C<sub>1-4</sub> alkyl may be prepared by subjecting the exposed amine in the compound of formula 13 to a reductive alkylation reaction by using sodium cyanoborohydride as a reducing agent under a weak acidic condition with C<sub>1-4</sub> aldehyde, and then removing amine protecting group P', according to the kind of amine protecting group, under the substantially same condition as in the deprotection reaction of amine protecting group P, which reaction



- 15 -

is used for the preparation of the compound of formula 1 from the compound of formula 4 as illustrated in Reaction scheme 2. Further, the compound of formula 3a, which is another starting material used in Reaction scheme 2 may be prepared by introducing an amine protecting group P, which is the same kind of protecting group as the previously defined amine protecting group P', into the compound of formula 13 to obtain the compound of formula 14 and, then, removing the amine protecting group P' in accordance with a suitable deprotection method selected from the previously presented deprotection methods depending on the kind of the amine protecting group.

The following Preparation Examples and Examples are intended to further illustrate the present invention without limiting its scope.

#### Preparation 1:

15 1-benzyl-4-methanesulfonyloxymethyl-4-hydroxymethyl-pyrrolidine-3-one-O-methyloxime

50g of 1-benzyl-4-ethoxycarbonyl-pyrrolidine-3-one was dissolved in 300ml of isopropanol and thereto 4ml of 10% NaOH and 20.7ml of formalin were added successively. The mixture was stirred for 30 minutes at room temperature and concentrated under the reduced pressure. 200ml of water was added to the concentrated residue. The resulting solution was extracted twice with each 200ml of ethylether, dried with magnesium sulfate, filtered and concentrated under the reduce pressure to give 46g of 1-benzyl-4-hydroxymethyl-4-ethoxycarbonyl-pyrroline-3-one(yield : 82.0%). The obtained compound was dissolved in 400ml of pyridine and thereto methoxylamine hydrochloride was added and stirred for 1 hour at room temperature. The reaction mixture was concentrated under the reduced pressure, diluted with 400ml of dichloromethane, washed with water and saline solution, dried with magnesium sulfate, filtered and concentrated under the reduced pressure to give 43g of 1-benzyl-4-hydroxymethyl-4-ethoxycarbonyl-pyrroline-3-one-O-methyloxi

- 16 -

me(yield : 84.6%). Thus obtained compound was dissolved in a solution of 22ml of triethylamine and 400ml of dichloromethane and cooled to 0-5°C and thereto 10ml of methanesulfonylchloride was added dropwise and the reaction temperature was slowly increased up to room temperature. The  
5 reaction mixture was stirred for 1 hour, washed with water and saline solution, dried with magnesium sulfate, filtered and concentrated under the reduced pressure to give 50g of 1-benzyl-4-methanesulfonyloxymethyl-4-ethoxycarbonyl-pyrroline-3-one-O-methyloxime(yield : 92.6%). It was dissolved in 200ml of tetrahydrofuran  
10 and thereto 13g of sodium borohydride and 400ml of ethyl alcohol were added successively at room temperature and 11g of lithium chloride was added slowly. The reaction mixture was stirred for 5 hours and poured into 300ml of ice water. The resulting solution was adjusted to pH 5-6 with diluted hydrochloric acid, concentrated under the reduced pressure to  
15 remove most organic solvents therefrom, then extracted twice with each 200ml of ethylether, dried with magnesium sulfate, filtered and concentrated under the reduced pressure. The residue was purified by silicagel column chromatography(ethylacetate:normal hexane=2:1) to give 42g of the titled liquid compound(yield : 94.3%).  
20 <sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 2.54(d, 1H), 2.84(d, 1H), 2.96(s, 3H), 3.30(s, 2H), 3.60~3.71(m, 4H), 3.77(s, 3H), 4.32~4.53(m, 2H), 7.22~7.27(m, 5H).

#### Preparation 2:

1-benzyl-4-methanesulfonyloxymethyl-4-azidomethyl-pyrrolidine-3-one-O-  
25 methyloxime.

42g of

1-benzyl-4-methanesulfonyloxymethyl-4-hydroxymethyl-pyrrolidine-3-one-O-methyloxime was dissolved in 400ml of dimethylformamide and thereto  
30 21g of sodium azide was added and the resulting solution was stirred for 6 hours at 110°C. The reaction mixture was concentrated under the reduce pressure, diluted with 300ml of ethylether, washed twice with each 200ml

- 17 -

of water and twice with each 200ml of saline solution, dried with magnesium sulfate, filtered and concentrated under the reduced pressure to give 31g of

1-benzyl-4-azidomethyl-4-hydroxymethyl-pyrrolidine-3-one-O-methyloxime  
5 (yield : 87.3%). The obtained compound and 18ml of triethylamine were added into 300ml of dichloromethane and cooled to 0-5°C, and thereto 9.0ml of methanesulfonylchloride was slowly added by dropping. The reaction temperature was increased up to room temperature and the mixture was stirred for 1 hour. The reaction mixture was washed with 200ml of water  
10 and 200ml of saline solution, dried with magnesium sulfate, filtered and concentrated under the reduced pressure and the concentrated residue was purified by silicagel column chromatography(ethylacetate:normal hexane=1:3) to give 38.8g of the titled compound(yield: 98.4%).

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 2.77(d, 2H), 2.98(s, 3H), 3.34(s, 2H), 3.57(s, 2H),  
15 3.65(s, 2H), 3.85(s, 3H), 4.31(s, 2H), 7.22~7.27(m, 5H).

#### Preparation 3:

t-butyl-6-benzyl-8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate.

20 10g of

1-benzyl-4-methanesulfonyloxymethyl-4-azidomethyl-pyrrolidine-3-one-O-methyloxime was dissolved in 100ml of ethyl acetate and thereto 5ml of 50% Raney nickel slurry was added and the resulting mixture was stirred for 3 hours under the pressure of hydrogen. The reaction mixture was  
25 filtered and concentrated under the reduced pressure to give 8.0g of 1-benzyl-4-methanesulfonyloxymethyl-4-aminomethyl-pyrrolidine-3-one-O-methyloxime(yield: 86%). The obtained compound was dissolved in 200ml of acetonitrile and thereto 3.9ml of 1,8-diazabicyclo[5,4,0]undec-7-ene was dropped, and the resulting mixture was stirred for 8 hours, concentrated  
30 under the reduce pressure, and dissolved in 150ml of dichloromethane, washed with 100ml of water and with 100ml of saline solution, dried with magnesium sulfate, filtered and concentrated under the reduced pressure to

- 18 -

give 4.0g of 6-benzyl-2,6-diazaspiro[3,4]octane-8-one-O-methyloxime(yield: 69.3%). The obtained compound and 2.5ml of triethylamine were dissolved in 50ml of dichloromethane and thereto 3.9g of di-t-butyldicarbonate. The resulting mixture was stirred for 4 hours, washed with 50ml of water, 5 dried with magnesium sulfate, filtered and concentrated under the reduced pressure. The concentrated residue was purified by silicagel column chromatography(ethylacetate:normal hexane:dichloromethane=3:5:1) to give 4.6g of the titled compound(yield: 80.9%).

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.36(s, 9H), 2.80(s, 2H), 3.24(s, 2H), 3.51(s, 2H), 10 3.78(d, 2H), 3.80(s, 3H), 4.24(d, 2H), 7.20~7.27(m, 5H).

Preparation 4:

t-butyl-8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate.

15 4.0g of t-butyl-6-benzyl-8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate was dissolved in 40ml of methanol and thereto 4.0g of 10% Pd-C was added. The resulting mixture was stirred for 2 hours under the pressure of hydrogen at 5°C, filtered and concentrated under the reduce pressure to give 1.3g of the titled compound(yield : 87.9%).

20 <sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.39(s, 9H), 3.18(s, 2H), 3.58(s, 2H), 3.78(d, 2H), 3.80(s, 3H), 4.05(d, 2H).

Preparation 5:

25 1-benzyl-4-methanesulfonyloxymethyl-4-hydroxymethyl-pyrrolidine-3-one-O-ethyloxime.

The titled compound was prepared by the same procedure to Preparation 1.

30 <sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.21(t, 3H, J=7.07Hz), 2.92(bs, 2H), 3.03(bs, 2H), 3.40(m, 2H), 3.72~3.75(m, 4H), 4.05~4.11(m, 2H), 4.35~4.42(m, 2H), 7.26~7.33(m, 5H).

## Preparation 6:

1-benzyl-4-methanesulfonyloxymethyl-4-azidomethyl-pyrrolidine-3-one-O-ethyloxime.

5

The titled compound was prepared by the same procedure to Preparation 2.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.14(t, 3H, J=7.08Hz), 2.63~2.72(dd, 2H, J=9.48Hz), 2.91(s, 3H), 3.29(s, 2H), 3.51(s, 2H), 3.58(s, 2H), 4.04(q, 2H, J=7.08Hz), 4.28(s, 2H), 7.24(m, 5H).

10

## Preparation 7:

t-butyl-6-benzyl-8-(ethoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate.

15 The titled compound was prepared by the same procedure to Preparation 3.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.19(m, 3H), 1.41(s, 9H), 2.85(bs, 2H), 3.30(bs, 2H), 3.64(bs, 2H), 3.80(bs, 2H), 4.07~4.11(m, 4H), 7.30(bs, 5H).

20 Preparation 8:

t-butyl-8-(ethoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate.

The titled compound was prepared by the same procedure to Preparation 4.

25 <sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.20(t, 3H, J=6.84Hz), 1.38(s, 9H), 3.32(s, 2H), 3.62(s, 2H), 3.88(d, 2H), 4.10~4.19(m, 4H), 4.97(s, 1H).

## Preparation 9:

6-benzyl-8-(methoxyimino)-2-methyl-2,6-diazaspiro[3,4]octane.

30

550mg of 6-benzyl-2,6-diazaspiro[3,4]octane-8-one-O-methyloxime was added to 10ml of ethanol and thereto 0.4ml of acetic acid and 176mg of

- 20 -

paraformaldehyde were added and the resulting mixture was stirred for 30 minutes at room temperature and thereto 370mg of sodium cyanoborohydride was added. The resulting mixture was stirred for 16 hours at room temperature, neutralized with aqueous solution of potassium carbonate and distilled under the reduced pressure and the obtained residue was added into 50ml of dichloromethane, washed with 50ml of water, dried with magnesium sulfate, filtered and concentrated under the reduced pressure. The residue was purified by silicagel column chromatography(methanol:normal hexane:dichloromethane=1:10:8) to give 350mg of the titled compound(yield: 60.1%).

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 2.38(s, 3H), 2.87(s, 2H), 3.19(s, 2H), 3.23(d, 2H), 3.29(d, 2H), 3.58(s, 2H), 3.89(s, 3H), 7.17~7.27(m, 5H).

Preparation 10:

8-(methoxyimino)-2-methyl-2,6-diazaspiro[3,4]octane.

340mg of 6-benzyl-8-(methoxyimino)-2-methyl-2,6-diazaspiro[3,4]octane was dissolved in 10ml of methanol and thereto 300mg of 10% Pd-C was added. The resulting mixture was stirred for 2 hours at 50°C under the pressure of hydrogen, filtered and concentrated under the reduced pressure to give 195mg of the titled compound(yield: 85.2%).

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 2.33(s, 3H), 3.23~3.28(m, 4H), 3.35(d, 2H), 3.56(s, 2H), 3.86(s, 3H).

Preparation 11:

7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid.

400mg of

1-cyclopropyl-6-fluoro-7-chloro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid and 840mg of t-butyl 8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate were added to

- 21 -

10ml of acetonitrile and the resulting mixture was stirred for 3 hours at 45-50°C. Then the precipitated solid was filtered and dried to give 650mg of the titled compound(yield:93.9%).

m.p. : 278-279°C

- 5 <sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.05(m, 2H), 1.27(m, 2H), 1.45(s, 9H), 3.61~3.67(m, 1H), 3.90(s, 3H), 3.94(s, 2H), 4.25(s, 2H), 4.27(s, 2H), 4.56(s, 2H), 8.04(d, 1H, J=11.71Hz), 8.68(s, 1H).

Preparation 12:

- 10 7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

400mg of

- 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and  
15 840mg of t-butyl 8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate were added to 10ml of acetonitrile and the resulting mixture was refluxed for 3 hours. Then the precipitated solid was filtered and dried to give 340mg of the titled compound(yield: 46.4%).

m.p. : 255~256°C

- 20 <sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.18(bs, 2H), 1.39(m, 2H), 1.45(s, 9H), 3.52(bs, 1H), 3.91~4.05(m, 7H), 4.27(d, 2H), 4.34(s, 2H), 7.00(d, 1H, J=7.07Hz), 7.94(d, 1H, J=13.67Hz), 8.64(s, 1H).

Preparation 13:

- 25 7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

150mg of

- 1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid  
30 and 320mg of t-butyl 8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate were added to 10ml of acetonitrile and the resulting mixture was refluxed for 7 hours and

- 22 -

then cooled to room temperature. The precipitated solid was filtered and dried to give 120mg of the titled compound(yield: 55.5%).

m.p. : 255~256°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.16(s, 2H), 1.29(d, 2H), 1.44(s, 9H), 3.92~3.94(m, 6H), 4.05(s, 2H), 4.22(d, 2H), 4.38(s, 2H), 7.89(d, 1H), 8.76(s, 1H).

Preparation 14:

7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-8-chloro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

10

300mg of

1-cyclopropyl-6,7-difluoro-8-chloro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid,

530mg

of

t-butyl

8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate and 2g of

15

Amberlite<sup>®</sup> IRA-420 were added to 10ml of acetonitrile and thereto 1ml of triethylamine was added by dropping. The resulting mixture was refluxed for 72 hours and then the resulting solid was filtered off. The filtrate was concentrated under the reduced pressure and thereto 10ml of ethylacetate was added and the resulting solution was stirred for 4 hours. The precipitated solid was filtered and dried to give 169mg of the titled compound(yield: 31.4%).

20

m.p. : 203~204°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.16(bs, 2H), 1.39(d, 2H), 1.44(s, 9H), 3.92~3.94(m, 6H), 4.03(s, 2H), 4.21(d, 2H), 4.38(s, 2H), 7.88(d, 1H, J=13.19Hz), 8.76(s, H).

25

Preparation 15:

7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-5-amino-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

30

750mg of

1-cyclopropyl-5-amino-6,7,8-trifluoro-4-oxo-1,4-dihydro-3-quinoline-



- 23 -

carboxylic acid, 1.05g of t-butyl 8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate and 4g of Amberlite® IRA-420 were added to 20ml of acetonitrile and thereto 2ml of triethylamine was added by dropping. The mixture was refluxed for 5 days and then 2ml of dimethylformamide was added thereto. The resulting mixture was stirred for 1 hour and thus precipitated solid was filtered off. The filtrate was concentrated under the reduced pressure and then to the resulting residue 10ml of acetonitrile was added and stirred for 1 hour. The precipitated solid was filtered and dried to give 420mg of the titled compound(yield: 30.9%).

m.p. : 256~257°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.05(s, 2H), 1.18(d, 2H), 1.44(s, 9H), 3.89~3.96(m, 6H), 3.99(s, 2H), 4.21(d, 2H), 4.34(s, 2H), 8.62(s, 1H).

15 Preparation 16:

7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

95mg of

1-(2,4-difluorophenyl)-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, 120mg of t-butyl 8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate and 400mg of Amberlite® IRA-420 were added to 10ml of acetonitrile and thereto 0.5ml of triethylamine was added by dropping. The resulting mixture was refluxed for 48 hours and thus precipitated solid was filtered off. To the filtrate 5ml of ethylether was added and the resulting mixture was stirred for 4 hours. The precipitated solid was filtered and dried to give 110mg of the titled compound(yield: 67.8%).

m.p. : 263~264°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.43(s, 9H), 3.64(s, 2H), 3.86~3.91(m, 2H), 3.92(s, 3H), 4.18~4.21(m, 4H), 5.91(d, 1H, J=6.84Hz), 7.18~7.24(m, 2H), 7.48(m, 1H), 8.06(d, 1H, J=13.68), 8.54(s, 1H).

## Preparation 17:

7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-

5 carboxylic acid.

110mg of

1-(2,4-difluorophenyl)-6-fluoro-7-chloro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and 120mg of t-butyl  
10 8-(methoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate were added to 10ml of acetonitrile and thereto 0.5ml of triethylamine was added dropwise. The resulting mixture was stirred for 4 hours at 50°C and then for 2 hours at the room temperature. The precipitated solid was filtered and dried to give 150mg of the titled compound(yield: 79.9%).

15 m.p. : 230~232°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.47(s, 9H), 3.82~3.92(m, 7H), 4.17~4.29(m, 4H), 7.07~7.13(m, 2H), 7.35~7.41(m, 1H), 8.12(d, 1H, J=12.20Hz), 8.64(s, 1H).

## Preparation 18:

20 7-[2-(t-butoxycarbonyl)-8-(ethoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid.

360mg of

25 1-cyclopropyl-6-fluoro-7-chloro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and 500mg of t-butyl 8-(ethoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate were added to 10ml of acetonitrile and thereto 1ml of triethylamine was added by dropping. The resulting mixture was stirred for 2 hours at 50°C and then for 1 hour  
30 at the room temperature. The precipitated solid was filtered and dried to give 380mg of the titled compound(yield: 57.9%).

m.p. : 261~262°C

- 25 -

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 1.06(s, 2H), 1.27~1.31(m, 5H), 1.45(s, 9H), 3.64~3.66(m, 1H), 3.96(d, 2H), 4.19~4.28(m, 6H), 4.57(s, 2H), 8.08(d, 1H, J=12.20Hz), 8.12(s, 1H).

## 5 Preparation 19:

7-[2-(t-butoxycarbonyl)-8-(ethoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-5-amino-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

10 400mg of

1-cyclopropyl-5-amino-6,7,8-trifluoro-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid, 680mg of t-butyl 8-(ethoxyimino)-2,6-diazaspiro[3,4]octane-2-carboxylate and 2g of Amberlite<sup>®</sup> IRA-420 were added to 15ml of acetonitrile and thereto 1.5ml of triethylamine was dropped and the resulting mixture was refluxed for 5 days and filtered. The filtrate was concentrated under the reduced pressure and to the resulting residue 10ml of isopropanol was added and the resulting solution was stirred for 1 hour at room temperature. The precipitated solid was filtered and dried to give 380mg of the titled compound(yield: 51.1%).

m.p. : 235~236°C

<sup>1</sup>H-NMR(CDCl<sub>3</sub>, ppm): 0.98(bs, 2H), 1.15~1.23(m, 5H), 1.34(s, 9H), 3.26~3.30(m, 1H), 3.86(d, 2H), 3.93(s, 2H), 4.06~4.12(m, 4H), 4.28(s, 2H), 8.53(s, 1H).

25

## Example 1.

1-Cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid methanesulfonate

30 350mg of

7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid

- 26 -

was dissolved in 5ml of dichloromethane and thereto 0.6ml of trifluoroacetic acid was dropped. The mixture was stirred for 5 hours at room temperature and thereto 10ml of ethylether was added. It was stirred additionally for 1 hour and thus precipitated solid was filtered, dissolved in 5 5ml of diluted NaOH and neutralized with diluted hydrochloric acid. The precipitate thus obtained was filtered and dried. The resulting solid was added to 5ml of 1N-methanesulfonic acid in ethanol and stirred for 1 hour. Thus obtained precipitate was filtered and dried to give 185g of the titled compound(yield : 47.8%).

10 m.p. : 228~229°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 0.97(s, 2H), 1.14(d, 2H), 2.48(s, 3H), 3.57(bs, 1H), 3.88(s, 3H), 4.06~4.17(m, 4H), 4.40(s, 2H), 4.49(s, 2H), 7.88(d, 1H, J=12.67Hz), 8.49(s, 1H).

15 Example 2.

1-Cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate

175mg of

20 7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid was dissolved in 5ml of dichloromethane and thereto 1ml of trifluoroacetic acid was added by dropping. The resulting mixture was stirred at room temperature for 18 hours, and thereto 10ml of ethylether was added. The 25 resulting precipitate was filtered and dried. Thus obtained solid was dissolved in 2ml of diluted NaOH and neutralized with diluted hydrochloric acid, and the resulting precipitate was filtered and dried. The solid thus obtained was added to 2ml of 1N-methanesulfonic acid in ethanol and stirred at room temperature for 3 hours. The precipitate was filtered and 30 dried to give 35mg of the titled compound(yield : 28.5%).

m.p. : 216~217°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 1.04(s, 2H), 1.22(d, 2H), 2.45(s, 3H),

- 27 -

3.62(bs, 1H), 3.84(s, 3H), 4.06~4.18(m, 6H), 4.23(s, 2H), 7.10(d, 1H, J=7.15Hz), 7.76(d, 1H, J=14.27Hz), 8.52(s, 1H).

### Example 3.

- 5 1-Cyclopropyl-6,8-difluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid

150mg of

- 7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid was dissolved in 5ml of dichloromethane and thereto 1ml of trifluoroacetic acid was added dropwise. The mixture was stirred for 5 hours at room temperature and thereto 10ml of ethylether was added. It was additionally stirred for 1 hour, and thus precipitated solid was filtered and dried. Thus  
15 obtained solid was dissolved in 5ml of diluted sodium hydroxide and neutralized with diluted hydrochloric acid. The resulting precipitate was filtered and dried to give 115mg of the titled compound(yield : 87.4%).

m.p. : 205~207°C

- <sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 1.16(s, 4H), 3.87~3.97(m, 4H), 4.06~  
20 4.33(m, 6H), 4.39(s, 2H), 7.77(d, 1H, J=13.15Hz), 8.63(s, 1H).

### Example 4

1-Cyclopropyl-6-fluoro-8-chloro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid

25

150mg of

- 7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-8-chloro-4-oxo-1,4-dihydro-3-quinolinecaboxylic acid was dissolved in 5ml of dichloromethane and thereto 0.2ml of  
30 trifluoroacetic acid was added dropwise. The mixture was stirred for 18 hours at room temperature, and thereto 10ml of pyridine and 10ml of water were added. It was distilled under the reduced pressure to remove

- 28 -

dichloromethane and stirred for 1 hour. The precipitated solid was filtered and dried to give the titled compound(67mg).

yield : 54.7%

m.p. : 220~221°C

- 5 <sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 0.95(s, 2H), 1.16(d, 2H), 3.89(s, 3H), 4.02~4.06(m, 4H), 4.13~4.23(m, 4H), 4.34(bs, 1H), 7.92(d, 1H, J=12.44Hz), 8.82(s, 1H).

#### Example 5

- 10 1-Cyclopropyl-5-amino-6,8-difluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate

420mg of

- 7-[2-(t-Butoxycabonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-5-amino-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid was dissolved in 10ml of dichloromethane and thereto 1ml of trifluoroacetic acid was added dropwise. The mixture was stirred at room temperature for 18 hours, and thereto 10ml of pyridine was added. It was distilled under the reduced pressure. The residue was purified by silica gel chromatography(chloroform:methyl alcohol:water=6:2:0.2). Thus obtained solid was added to 2ml of 1N-methansulfonic acid in ethanol, stirred for 3 hours at room temperature. The precipitated solid was filtered and dried to give the titled compound(165mg)

yield : 39.6%

- 25 m.p. : 238~239°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 1.09(bs, 4H), 2.49(s, 3H), 3.89(s, 3H), 3.92~3.99(m, 1H), 4.08~4.20(m, 6H), 4.35(s, 2H), 8.50(s, 1H).

#### Exmample 6

- 30 1-(2,4-Difluorophenyl)-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid dimethanesulfonate

90mg of

7-[2-(t-butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid was dissolved in 5ml of dichloromethane and thereto 0.1ml of trifluoroacetic acid was added by dropping. The mixture was stirred at room temperature for 12 hours and thereto 5ml of pyridine was added. The mixture was distilled under the reduced pressure to remove dichloromethane and thereto 5ml of water was added. It was stirred at room temperature for 2 hours. The resulting precipitate was filtered and dried, and added to 2ml of 1N-methansulfonic acid in ethanol and stirred at room temperature for 1 hour. Thus precipitated solid was filtered and dried to give the titled compound(45mg).

yield : 43.1%

m.p. : 216~217°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 2.49(s, 6H), 3.74~4.09(m, 11H), 5.93(d, 1H), 7.24(m, 1H), 7.45(m, 1H), 7.88(m, 1H), 7.89(d, 1H, J=14.40Hz), 8.60(s, 1H).

#### Example 7

1-(2,4-Difluorophenyl)-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate

140mg of

7-[2-(t-Butoxycarbonyl)-8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid was dissolved in 5ml of dichloromethane and thereto 0.2ml of trifluoroacetic acid was added by dropping. The mixture was stirred at room temperature for 12 hours and thereto 5ml of pyridine was added. It was distilled under the reduced pressure to remove dichloromethane and thereto 5ml of water was added. It was stirred at room temperature for 2 hours. The resulting precipitate was filtered and dried. Thus obtained solid

- 30 -

was added to 2ml of 1N-methansulfonic acid in ethanol and stirred at room temperature for 1 hour. The precipitate was filtered and dried to give the titled compound(95mg).

yield : 68.3%

5 m.p. : 201 ~ 202°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 2.49(s, 3H), 3.85(s, 3H), 3.88~4.10(m, 8H), 7.23~7.26(m, 1H), 7.40~7.46(m, 1H), 7.70~7.76(m, 1H), 8.07(d, 1H, J=12.44Hz), 8.76(s, 1H).

10 Example 8

1-Cyclopropyl-6-fluoro-7-[8-(ethoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate

380mg of

15 7-[2-(t-Butoxycarbonyl)-8-(ethoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid was dissolved in 5ml of dichloromethane and thereto 0.6ml of trifluoroacetic acid was added dropwise. The mixture was stirred at room temperature for 12 hours and thereto 3ml of pyridine was added. It was  
20 distilled under the reduced pressure to remove dichloromethane and 1ml of water was added thereto. It was stirred at room temperature for 2 hours. Thus precipitated solid was filtered and dried. The resulting solid was added to 2ml of 1N-methansulfonic acid in ethanol and stirred at room temperature for 1 hour. The precipitate was filtered and dried to give  
25 220mg of the titled compound(yield : 58.3%).

m.p. : 211 ~ 212°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 1.02(bs, 2H), 1.19~1.28(m, 5H), 2.48(s, 3H), 3.63~3.68(m, 1H), 4.06~4.20(m, 5H), 4.38(s, 2H), 4.51(s, 2H), 7.97(d, 1H, J=12.44Hz), 8.55(s, 1H).

30

Example 9

1-Cyclopropyl-5-amino-6,8-difluoro-7-[8-(ethoxyimino)-2,6-diazaspiro[3,4]



oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate

380mg of

7-[2-(t-Butoxycabonyl)-8-(ethoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-1-

- 5 cyclopropyl-5-amino-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid was dissolved in 10ml of dichloromethane and thereto 0.7ml of trifluoroacetic acid was dropped. The mixture was stirred at room temperature for 18 hours and thereto 10ml of pyridine was added. It was distilled under the reduced pressure to remove the solvent. The residue
- 10 was purified by silica gel chromatography(chloroform : methyl alcohol: water = 6 : 2 : 0.2). Thus obtained solid was added to 1.5ml of 1N-methansulfonic acid in ethanol and stirred at room temperature for 3 hours. The resulting precipitate was filtered and dried to give 180mg of the titled compound(yield : 47.1%).

- 15 m.p. : 221~222°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 0.96~1.02(m, 4H), 1.15(t, 3H, J=7.08Hz), 2.49(s, 3H), 3.87(d, 1H), 3.98~4.12(m, 8H), 4.22(s, 2H), 8.42(s, 1H).

- 20 Example 10

1-Cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2-methyl-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

300mg of

- 25 1-Cyclopropyl-6-fluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid was added to 10ml of ethanol, and thereto 0.2ml of acetic acid was dropped and 42mg of p-formaldehyde was added. The mixture was stirred at room temperature for 30 minutes, and thereto 85mg of sodium cyanoborohydride was added.
- 30 It was stirred at room temperature for 2 hours. The resulting precipitate was filtered and dried to give 260mg of the titled compound(yield : 83.7%).
- m.p. : 225~227°C

- 32 -

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 0.95(s, 2H), 1.16(d, 2H), 2.49(s, 3H), 3.58~3.61(m, 1H), 3.87(s, 3H), 4.08~4.18(m, 4H), 4.34(s, 2H), 4.46(s, 2H), 7.93(d, 1H, J=12.43Hz), 8.51(s, 1H).

#### 5. Example 11

1-Cyclopropyl-5-amino-6,8-difluoro-7-[8-(methoxyimino)-2-methyl-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid

300mg of

- 10 1-Cyclopropyl-5-amino-6,8-difluoro-7-[8-(methoxyimino)-2,6-diazaspiro[3,4]oct-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid was added to 10ml of ethanol, and thereto 0.2ml of acetic acid was dropped and 44mg of p-formaldehyde was added. It was stirred at room temperature for 30 minutes and thereto 91mg of sodium cyanoborohydride was added. It was  
15 stirred at room temperature for 2 hours. The resulting precipitate was filtered to give 280mg of the titled compound(yield : 90.4%).

m.p. : 220~222°C

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>+CF<sub>3</sub>COOD, ppm): 1.15~1.23(m, 4H), 2.64(s, 3H), 4.05(s, 3H), 4.06~4.10(m, 1H), 4.20~4.39(m, 6H), 4.47(s, 2H), 8.62(s, 1H).

20

#### Experimental 1. In vitro Antibacterial Activity Test

In order to evaluate the in vitro antibacterial activities of the compounds prepared in examples according to the present invention the  
25 minimum inhibitory concentrations(MIC, µg/ml) were measured by the 2-fold agar dilution method(Hoechst 345) using the Muller-Hinton agar.

10<sup>7</sup> cfu/ml of bacteria were inoculated and cultured for 18 hours at 37°C and then the antibacterial activities were measured. For the methicillin resistant strains the activities were measured after 48 hours of cultivation  
30 at 30°C. Hoechst Standard strains were used for the testings.

The result is shown in the next tables 1 and 2.

Table 1. In vitro Antibacterial Activity ( $\mu\text{g/ml}$ )

Strains \ Compounds		Example 1	Example 2	Example 3	Example 4
5	<i>Streptococcus pyogens</i> 308A	0.098	0.195	0.391	0.195
	<i>Streptococcus pyogens</i> 77A	0.007	0.007	0.025	0.013
	<i>Streptococcus faecium</i> MD 8b	0.049	0.098	0.098	0.098
10	<i>Staphylococcus aureus</i> SG511	0.007	0.013	0.025	0.013
	<i>Staphylococcus aureus</i> 285	0.025	0.049	0.049	0.049
	<i>Staphylococcus aureus</i> 503	0.025	0.049	0.098	0.025
	<i>Esherichia coli</i> 078	0.013	0.025	0.098	0.025
15	<i>Esherichia coli</i> DC0	0.195	0.198	0.391	0.391
	<i>Esherichia coli</i> DC2	0.025	0.013	0.025	0.049
	<i>Esherichia coli</i> TEM	0.025	0.049	0.049	0.049
	<i>Esherichia coli</i> 1507E	0.025	0.049	0.049	0.049
20	<i>Pseudomonas aeruginosa</i> 9027	0.781	0.781	1.563	0.781
	<i>Pseudomonas aeruginosa</i> 1592E	0.391	0.391	0.781	0.781
	<i>Pseudomonas aeruginosa</i> 1771	0.391	0.391	1.563	0.781
	<i>Pseudomonas aeruginosa</i> 1771M	0.391	0.391	0.781	0.391
25	<i>Salmonella typhimurium</i>	0.013	0.025	0.025	0.025
	<i>Klebsiella oxytoca</i> 1082E	0.004	0.007	0.007	0.004
	<i>Klebsiella aerogenes</i> 1522E	0.049	0.098	0.098	0.098
	<i>Enterobacter cloacae</i> P99	0.025	0.049	0.049	0.049
30	<i>Enterobacter cloacae</i> 1321E	0.013	0.025	0.025	0.025

(μg/ml)

Strains \ Compounds		Example 5	Example 6	Example 77	Example 8
5	<i>Streptococcus pyogens</i> 308A	0.025	0.195	0.195	0.098
	<i>Streptococcus pyogens</i> 77A	<0.002	0.013	0.013	0.007
	<i>Streptococcus faecium</i> MD 8b	0.025	0.195	0.098	0.098
10	<i>Staphylococcus aureus</i> SG511	<0.002	0.049	0.013	0.007
	<i>Staphylococcus aureus</i> 285	0.007	0.098	0.049	0.025
	<i>Staphylococcus aureus</i> 503	<0.002	0.049	0.025	0.013
15	<i>Esherichia coli</i> 078	<0.002	0.049	0.049	0.013
	<i>Esherichia coli</i> DC0	0.098	0.781	0.781	0.391
	<i>Esherichia coli</i> DC2	0.013	0.098	0.098	0.025
	<i>Esherichia coli</i> TEM	0.013	0.195	0.098	0.025
	<i>Esherichia coli</i> 1507E	0.007	0.195	0.195	0.049
20	<i>Pseudomonas aeruginosa</i> 9027	0.781	3.125	1.563	1.563
	<i>Pseudomonas aeruginosa</i> 1592E	0.391	1.563	1.563	0.781
	<i>Pseudomonas aeruginosa</i> 1771	0.391	1.563	1.563	0.781
	<i>Pseudomonas aeruginosa</i> 1771M	0.195	1.563	0.781	0.781
25	<i>Salmonella typhimurium</i>	<0.002	0.049	0.049	0.013
	<i>Klebsiella oxytoca</i> 1082E	<0.002	0.013	0.013	0.004
	<i>Klebsiella aerogenes</i> 1522E	0.025	0.391	0.195	0.098
	<i>Enterobacter cloacae</i> P99	0.007	0.098	0.098	0.025
30	<i>Enterobacter cloacae</i> 1321E	0.004	0.098	0.049	0.025

( $\mu\text{g/ml}$ )

Strains \ Compounds		Example 9	Example 10	Example 11	Ciproflo xacin	Sparflo xacin
5	<i>Streptococcus pyogens</i> 308A	0.025	0.098	0.013	3.125	0.391
	<i>Streptococcus pyogens</i> 77A	0.004	0.013	0.004	0.781	0.195
	<i>Streptococcus faecium</i> MD 8b	0.049	0.098	0.049	0.391	0.391
	<i>Staphylococcus aureus</i> SG511	<0.002	0.013	<0.002	0.195	0.098
10	<i>Staphylococcus aureus</i> 285	0.007	0.049	0.007	0.781	0.049
	<i>Staphylococcus aureus</i> 503	<0.002	0.025	0.004	0.391	0.049
	<i>Escherichia coli</i> 078	0.004	0.013	<0.002	0.004	0.004
	<i>Escherichia coli</i> DC0	0.195	0.391	0.098	0.195	0.195
15	<i>Escherichia coli</i> DC2	0.013	0.049	0.013	0.049	0.025
	<i>Escherichia coli</i> TEM	0.013	0.049	0.013	0.007	0.013
	<i>Escherichia coli</i> 1507E	0.013	0.049	0.013	0.007	0.025
	<i>Pseudomonas aeruginosa</i> 9027	0.781	0.781	0.781	0.195	0.781
20	<i>Pseudomonas aeruginosa</i> 1592E	0.781	0.781	0.781	0.195	0.781
	<i>Pseudomonas aeruginosa</i> 1771	0.781	0.781	0.781	0.195	0.781
	<i>Pseudomonas aeruginosa</i> 1771M	0.391	0.781	0.391	0.049	0.195
	<i>Salmonella typhimurium</i>	0.007	0.049	0.007	0.007	0.007
25	<i>Klebsiella oxytoca</i> 1082E	<0.002	0.007	<0.002	<0.002	<0.002
	<i>Klebsiella aerogenes</i> 1522E	0.049	0.098	0.049	0.013	0.025
	<i>Enterobacter cloacae</i> P99	0.007	0.049	0.013	0.007	0.007
	<i>Enterobacter cloacae</i> 1321E	0.007	0.025	0.004	<0.002	0.004
30						

Table 2. In vitro Antibacterial Activity against resistant strains.

( $\mu\text{g/ml}$ )

Strains \ Compounds		Example 1	Example 5	Example 9	Example 11	Ciproflox acin	Sparflox acin
5	<i>Staphylococcus aureus</i> 88E	0.049	0.007	0.007	0.007	0.781	0.098
	<i>Staphylococcus aureus</i> 121E	0.049	0.013	0.013	0.013	0.781	0.098
	<i>Staphylococcus aureus</i> 208E	0.049	0.007	0.013	0.013	0.781	0.098
	<i>Staphylococcus aureus</i> 256E	0.025	0.007	0.013	0.007	0.781	0.098
10	<i>Staphylococcus aureus</i> 690E	0.025	0.007	0.007	0.007	0.391	0.049
	<i>Staphylococcus aureus</i> 692E	0.025	0.004	0.007	0.007	0.391	0.049
	<i>Staphylococcus aureus</i> 693E	0.049	0.007	0.013	0.013	0.391	0.049
	<i>Staphylococcus aureus</i> 694E	0.049	0.007	0.013	0.013	0.391	0.098
15	<i>Staphylococcus aureus</i> 695E	0.049	0.007	0.013	0.013	0.391	0.049
	<i>Staphylococcus aureus</i> 697E	0.013	<0.002	0.004	0.004	0.391	0.049
	<i>Staphylococcus aureus</i> 701E	0.049	0.007	0.013	0.013	0.391	0.098
	<i>Staphylococcus aureus</i> 703E	0.049	0.007	0.013	0.013	0.391	0.098
20	<i>Staphylococcus aureus</i> 179	0.781	0.098	0.098	0.195	12.500	6.250
	<i>Staphylococcus aureus</i> 241	0.781	0.098	0.098	0.195	12.500	6.250
	<i>Staphylococcus aureus</i> 293	0.781	0.098	0.098	0.195	12.500	6.250
	<i>Staphylococcus aureus</i> 303	0.781	0.098	0.098	0.195	12.500	3.125
25	<i>Staphylococcus aureus</i> 8236	0.781	0.098	0.098	0.195	12.500	6.250
	<i>Staphylococcus epidermidis</i> 178	1.563	0.391	0.391	0.781	50.000	6.250
	<i>Staphylococcus epidermidis</i> 291	1.563	0.391	0.391	0.781	50.000	6.250

- 37 -

## Experimental 2. Acute Toxicity Test.

In the acute toxicity test of the quinolonecarboxylic acid derivatives prepared in examples according to the present invention ICR mice of 23-25g were used. Each group of mice comprised 5 male and 5 female mice and each sample compound was distributed into 5 doses.

After mice were starved for 24 hours only with water, samples diluted in 0.2ml of 0.1N NaOH and respectively adjusted to a predetermined dose were injected into the vein of mouse tails. After 1 hour from the injection mice was fed and then during 14 days lethality was observed.

10

As the result, the values of  $LD_{50}$ (mg/kg) of quinolonecarboxylic acid derivatives and its pharmaceutically acceptable salts according to the invention were of over 320, whereby it was proved that the compounds of the invention have high safety as antibacterial agents.

15

### Effect of the invention


The quinolonecarboxylic acid derivatives according to the present invention are very safe compounds as having very low toxicity, and they have more improved antibacterial activity than that of known quinolone antibacterial agents against gram positive bacteria, good antibacterial activity against gram negative bacteria and especially excellent antibacterial activity against methicillin resistant bacteria and known quinolone resistant bacteria.

Accordingly, the quinolonecarboxylic acid derivatives of the present invention are very useful as antibacterial agents.

30


What is claimed is:

1. A quinolonecarboxylic acid derivative represented by following formula 1, or a pharmaceutically acceptable salt or an isomer thereof:



Wherein, A is C-H, C-F, C-Cl, C-O-CH<sub>3</sub> or N; Y is H or amino; R<sub>1</sub> is cyclopropyl or 2,4-difluorophenyl; R<sub>2</sub> is C<sub>1-4</sub> alkyl; and R<sub>3</sub> is H or C<sub>1-4</sub> alkyl.

2. A process for preparing a quinolonecarboxylic acid derivative, which comprises conducting coupling reaction of the compound of formula 2 with the compound of formula 3 under the presence of an acid acceptor to obtain the compound of formula 1:



Wherein, A is C-H, C-F, C-Cl, C-O-CH<sub>3</sub> or N; Y is H or amino; R<sub>1</sub> is cyclopropyl or 2,4-difluorophenyl; R<sub>2</sub> is C<sub>1-4</sub> alkyl; R<sub>3</sub> is H or C<sub>1-4</sub> alkyl; and X is a halogen atom.



- 39 -

3. The process of claim 2, wherein an ion-exchange resin selected from the group consisting of Amberlite<sup>®</sup> IRA-420, Amberlite<sup>®</sup> IRA-900 and Amberlite<sup>®</sup> IRA-64 is used for increasing the reactivity of the condensation reaction.

5


4. A process for preparing a quinolonecarboxylic acid derivative, which comprises conducting coupling reaction of the compound of formula 2 with the compound of formula 3a under the presence of an acid acceptor to obtain the compound of formula 4, and removing the amine protecting group(P) from the compound of formula 4 to obtain the compound of formula 1 wherein R<sub>3</sub> is H, said process optionally further comprising  
10 subjecting the compound of formula 1 wherein R<sub>3</sub> is H to a reductive alkylation reaction using C<sub>1-4</sub> aldehyde to obtain a compound of formula 1 wherein R<sub>3</sub> is C<sub>1-4</sub> alkyl:

15

20

25

30




Wherein, A is C-H, C-F, C-Cl, C-O-CH<sub>3</sub> or N; Y is H or amino; R<sub>1</sub> is cyclopropyl or 2,4-difluorophenyl; R<sub>2</sub> is C<sub>1-4</sub> alkyl; R<sub>3</sub> is H or C<sub>1-4</sub>

alkyl; X is a halogen atom; and P is an amine protecting group.

5. A 8-alkoxyimino-2,6-diazaspiro[3.4]octane derivative of formula 3:

5




10

Wherein, R<sub>2</sub> is C<sub>1-4</sub> alkyl, and R<sub>3</sub> is H or C<sub>1-4</sub> alkyl.

6. A process for preparing the compound of formula 3, which comprises converting the compound of formula 5 to an oxime compound of formula 7, subjecting the oxime compound to cyclization reaction to obtain the compound of formula 13 and subjecting the compound of formula 13 to deprotection reaction, or a reductive alkylation reaction with a lower aldehyde followed by a deprotection reaction to obtain the compound of formula 3:

20




25

Wherein, R<sub>2</sub> is C<sub>1-4</sub> alkyl; R<sub>3</sub> is H or C<sub>1-4</sub> alkyl; and P' is an amino protecting group.

7. The process of claim 6, wherein the compound of formula 5 is converted to an oxime compound by reacting it with formaldehyde to obtain the compound of formula 6 and then reacting the compound of formula 6 with alkoxyamine to obtain the alkoxyimino compound of


30

formula 7:




Wherein,  $R_2$  is  $C_{1-4}$  alkyl; and  $P'$  is an amino protecting group.


8. The process of claim 6, wherein the cyclization reaction comprises: converting the hydroxy group(-OH) in the compound of formula 7 to leaving group L selected from the group consisting of methansulfonyloxy, p-toluenesulfonyloxy and halogen to obtain the compound of formula 8; reducing an ester group in the compound of formula 8 to an alcohol to obtain an alcohol compound of formula 9; substituting the leaving group L in the compound of formula 9 with an azido group to obtain the compound of formula 10; converting an hydroxy group in the compound of formula 10 to leaving group L to obtain the compound of formula 11; reducing an azido group in the compound of formula 11 to a primary amine to obtain the compound of formula 12; and subjecting the compound of formula 12 to a cyclization reaction to obtain the compound of formula 13:




30



11



12



13

Wherein, R<sub>2</sub> is C<sub>1-4</sub> alkyl; and P' is an amino protecting group.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 98/00185

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>6</sup>: C 07 D 487/10; A 61 K 31/47

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>6</sup>: C 07 D 487/00; A 61 K 31/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIL database, Derwent Publ. Ltd., London (GB)

Questel database, file CA; Questel Orbit Imagination (ed. 1995)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 722 941 A2 (ELI LILLY AND COMPANY) 24 July 1996 (24.07.96), totality.	1-8
A	Database WPIL on Questel, week 9519, Derwent Publications Ltd., AN 95-144821, JP 707110 A (HOKURIKU PHARM. CO. LTD.), abstract.	1-8
A	EP 0 643 058 A1 (DAIICHI PHARMACEUTICAL CO.) 15 March 1995 (15.03.95), totality.	1-8
A	EP 0 550 025 A1 (KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY) 07 July 1993 (07.07.93), totality.	1-8
A	Database WPIL on Questel, week 9412, Derwent Publications Ltd., AN 94-097812, JP 6049060 A (HOKURIKU PHARM. CO. LTD.), abstract.	1-8
A	Database WPIL on Questel, week 9412, Derwent Publications Ltd., AN 94-097811, JP 6049059 A (HOKURIKU PHARM. CO. LTD.), abstract.	1-8
A	Database WPIL on Questel, week 9433, Derwent Publications Ltd., AN 94-269425, JP 6199834 A (HOKURIKU	1-8

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 September 1998 (15.09.98)

Date of mailing of the international search report

30 September 1998 (30.09.98)

Name and mailing address of the ISA/  
Austrian Patent Office  
Kohlmarkt 8-10; A-1014 Vienna  
Facsimile No. 1/53424/535

Authorized officer  
Weniger

Telephone No. 1/53424/341

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR 98/00185

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	PHARM. CO. LTD.), abstract.	
A	EP 0 357 047 B1 (DAIICHI SEIYAKU CO.) 07 March 1990 (07.03.90), totality.	1-8
A	US 4 638 067 A (TOWNLEY P. CULBERTSON et al.) 20 January 1987 (20.01.87), totality.	1-8
A	EP 0 153 165 A2 (WARNER LAMBERT COMPANY) 28 August 1985 (28.08.85), totality.	1-8
A	EP 0 529 688 A2 (DAIICHI PHARMACEUTICAL CO.) 03 March 1993 (03.03.93), totality.	6-8

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application N .

PCT/KR 98/00185

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication		Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets		Datum der Veröffentlichung Publication date Date de publication	
EP A2	722941	24-07-96		AU A1	46516/96	07-08-96	
				BR A	9607077	18-11-97	
				CA AA	2210220	25-07-96	
				CZ A3	9702207	18-02-98	
				FI A	9730224	16-07-97	
				FI A0	9730224	16-07-97	
				NO A0	973281	15-07-97	
				NO A	973281	08-09-97	
				PL A1	321851	22-12-97	
				US A	5763321	19-11-96	
				WO A1	9622290	25-07-96	
				US A	614523	25-03-97	
				US A	627196	06-05-97	
				US A	741789	21-04-98	
				US A	5789402	04-08-98	
EP A1	643058	15-03-95		AU A1	72862/94	23-03-95	
				AU B2	679094	19-06-97	
				BG A	990335	31-05-99	
				CA AA	2131761	11-03-96	
				CN A	1106006	02-08-96	
				CZ A3	9402176	15-03-96	
				FI A0	9441174	09-09-94	
				FI A	9441174	11-03-95	
				HR A1	940506	30-04-95	
				HU A0	9402597	28-11-94	
				HU A2	68541	28-06-95	
				IL A0	110909	28-11-94	
				JP A2	7126266	16-05-94	
				LV A	113222	20-06-96	
				LV B	113222	20-10-96	
				NO A0	943313	08-09-94	
				NO A	943313	14-03-95	
				NZ A	264423	26-07-96	
				PL A1	304989	30-03-95	
				SI A	9400349	30-04-95	
				SK A3	1076/94	10-05-95	
				US A	5693814	02-12-97	
				ZA A	9406853	24-04-95	
EP A1	550025	07-07-93		KR B1	9611370	22-08-96	
EP B1	357047	03-11-93		AT E	96791	15-11-93	
				AT E	160141	15-11-93	
				AU A1	41006/89	08-03-90	
				AU B2	1419891	06-03-90	
				CA A1	1336090	27-08-90	
				CN A	1040790	28-03-90	
				CN A	1100095	15-03-91	
				CN B	1028102	05-04-91	
				CN B	1036193	22-10-97	
				DE CO	68910441	09-10-93	
				DE T2	68910441	03-06-93	
				DE CO	68928447	18-12-94	
				DE T2	68928447	18-06-98	
				DK A0	4262/89	30-08-90	
				DK A	4262/89	01-06-90	
				EP A1	357047	07-07-93	
				EP A2	357047	03-06-96	
				EP A3	357047	10-03-96	
				EP B1	357047	12-11-97	
				EP B2	357047	16-12-97	
				FI A0	940455	29-08-94	
				FI A	940455	01-06-94	
				FI A	940455	14-09-94	
				FI A0	940455	14-09-94	
				FI B	92703	15-09-94	
				FI C	92703	27-12-94	
				IE B	63493	03-08-94	
				IL A0	91474	29-04-90	
				IL A1	91474	30-05-94	
				IN A	170262	07-03-92	
				JP A2	8333337	17-10-96	
				NO A0	893453	29-08-96	
				NO A	893453	01-03-96	
				NO B	177638	17-07-95	
				NO C	230484	25-10-95	
				NZ A	230484	25-06-91	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 98/00185

CA	A1	1289956	01-10-91
DE	CO	3574972	01-03-91
DK	AO	687786	14-03-91
DK	A	687786	16-03-91
DK	B	1618899	26-03-91
DK	C	1618899	03-03-92
EP	A2	153165	28-08-85
EP	A3	153165	03-09-86
EP	B1	153165	12-12-90
EP	B2	153165	17-01-91
EP	A1	540441	01-03-91
EP	A5	540441	01-06-91
EP	A1	6705422	16-07-91
EP	AO	8500854	24-09-86
EP	A	8500854	24-09-86
EP	B	8500854	24-09-86
EP	C	8500854	24-09-86
EP	A2	8500854	24-09-86
EP	A1	8500854	24-09-86
EP	A2	6021477	28-10-91
EP	B4	7055945	14-06-92
EP	A2	7173160	11-07-92
EP	B2	2604134	30-04-93
KR	E1	9004985	16-07-90
NO	A	850614	19-08-85
NO	B	161370	02-05-89
NO	C	161370	09-08-89
NZ	A	211137	30-08-89
PH	A	20942	05-08-89
PT	A	79971	01-06-89
PT	B	79971	02-02-89
ZA	A	8500854	24-09-86
EP A2	153165	28-08-85	
AU	A1	38563785	22-08-85
AU	B2	581204	16-03-85
CA	A1	1220824	21-04-87
DE	CO	3580855	24-01-91
EP	A3	153165	03-09-86
EP	B1	153165	12-12-90
JP	A2	6101033	17-01-91
US	A	4573170	25-03-85
ZA	A	8500743	25-09-85
EP A2	529688	03-03-93	
AT	E	96791	15-11-93
AT	E	160141	15-11-93
AU	A1	41006789	08-03-90
AU	B2	619891	06-03-90
CA	A1	1036090	27-06-90
CN	A	1040790	28-03-90
CN	A	1100095	15-03-91
CN	B	1036193	05-04-91
CN	B	1036193	23-10-91
DE	CO	68910441	09-13-91
DE	T2	68910441	03-03-94
DE	CO	68910447	18-12-91
DE	T2	68910447	18-06-92
DK	AO	42262789	30-08-92
DK	A	42262789	01-03-93
EP	A1	927047	07-03-93
EP	A2	927047	10-03-93
EP	B1	927047	03-11-93
EP	B2	927047	12-11-93
EP	T2	927047	16-13-93
EP	A1	2111029	01-03-94
EP	AO	894045	29-03-94
EP	A	894045	01-03-94
EP	AO	934016	14-09-94
EP	B	934016	14-09-94
EP	C	934016	15-09-94
EP	B	934016	27-13-94
EP	A1	634922	03-08-94
EP	AO	91474	29-04-90
EP	A1	91474	30-05-94
EP	A	1702262	07-03-92
EP	A2	8333367	17-13-92
EP	AO	8934552	29-08-92
EP	A	8934552	01-03-93
EP	B	1776388	17-07-93
EP	C	1776388	25-10-93
EP	A	230484	23-06-94
EP	A	91602	08-03-90
EP	B	91602	31-03-90
EP	A	886723	15-02-94
EP	A	886723	16-04-96
EP	A2	9095176	19-04-91



### Information on patent family members

PCT/KR 98/00185

Form PCT/ISA/210 (patent family annex) (July 1998)

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 98/00185

HR	A1	930082	30-04-96
SI	A	B911674	31-10-97
YU	A	1674/B9	30-04-91
RU	C1	2094432	27-10-97
ZA	A	B906607	27-03-91